{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:45:50Z","timestamp":1794408350326,"version":"4.9.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Quanzhou City Science & Technology Program of China","award":["No. 2022NS080"],"award-info":[{"award-number":["No. 2022NS080"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92282-4","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T18:35:20Z","timestamp":1742582120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Mechanisms of rifaximin inhibition of hepatic fibrosis in mice with metabolic dysfunction associated steatohepatitis through the TLR4\/NF\u03baB pathway"],"prefix":"10.1038","volume":"15","author":[{"given":"Ting","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyuan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weitao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiyong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"6","key":"92282_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79(6), 1542\u20131556. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003 (2023).","journal-title":"J. Hepatol."},{"issue":"16","key":"92282_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","volume":"9","author":"M Benedict","year":"2017","unstructured":"Benedict, M. & Zhang, X. Non-alcoholic fatty liver disease: An expanded review. World J. Hepatol. 9(16), 715\u2013732. https:\/\/doi.org\/10.4254\/wjh.v9.i16.715 (2017).","journal-title":"World J. Hepatol."},{"issue":"7","key":"92282_CR3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/s2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher, G., Tilg, H. & Byrne, C. D. Non-alcoholic fatty liver disease: A multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol. Hepatol. 6(7), 578\u2013588. https:\/\/doi.org\/10.1016\/s2468-1253(21)00020-0 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"92282_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/hep.29113","volume":"66","author":"A Unalp-Arida","year":"2017","unstructured":"Unalp-Arida, A. & Ruhl, C. E. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology 66(1), 84\u201395. https:\/\/doi.org\/10.1002\/hep.29113 (2017).","journal-title":"Hepatology"},{"issue":"5","key":"92282_CR5","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/hep.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5), 1797\u20131835. https:\/\/doi.org\/10.1097\/hep.0000000000000323 (2023).","journal-title":"Hepatology"},{"issue":"5","key":"92282_CR6","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52(5), 1836\u20131846. https:\/\/doi.org\/10.1002\/hep.24001 (2010).","journal-title":"Hepatology"},{"issue":"8","key":"92282_CR7","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","volume":"150","author":"MV Machado","year":"2016","unstructured":"Machado, M. V. & Diehl, A. M. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology 150(8), 1769\u20131777. https:\/\/doi.org\/10.1053\/j.gastro.2016.02.066 (2016).","journal-title":"Gastroenterology"},{"issue":"1","key":"92282_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","volume":"76","author":"F Bessone","year":"2019","unstructured":"Bessone, F., Razori, M. V. & Roma, M. G. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell. Mol. Life Sci. 76(1), 99\u2013128. https:\/\/doi.org\/10.1007\/s00018-018-2947-0 (2019).","journal-title":"Cell. Mol. Life Sci."},{"issue":"7","key":"92282_CR9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.freeradbiomed.2007.12.029","volume":"44","author":"SK Mantena","year":"2008","unstructured":"Mantena, S. K. et al. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol. Med. 44(7), 1259\u20131272. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2007.12.029 (2008).","journal-title":"Free Radic Biol. Med."},{"issue":"4","key":"92282_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nrd.2015.3","volume":"15","author":"G Musso","year":"2016","unstructured":"Musso, G., Cassader, M. & Gambino, R. Non-alcoholic steatohepatitis: Emerging molecular targets and therapeutic strategies. Nat. Rev. Drug Discov. 15(4), 249\u2013274. https:\/\/doi.org\/10.1038\/nrd.2015.3 (2016).","journal-title":"Nat. Rev. Drug Discov"},{"issue":"23","key":"92282_CR11","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.3748\/wjg.v20.i23.7381","volume":"20","author":"K Miura","year":"2014","unstructured":"Miura, K. & Ohnishi, H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J. Gastroenterol. 20(23), 7381\u20137391. https:\/\/doi.org\/10.3748\/wjg.v20.i23.7381 (2014).","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"92282_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1053\/j.gastro.2016.06.022","volume":"151","author":"K Rahman","year":"2016","unstructured":"Rahman, K. et al. Loss of junctional adhesion molecule A promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology 151(4), 733\u2013746. https:\/\/doi.org\/10.1053\/j.gastro.2016.06.022 (2016). .e12.","journal-title":"Gastroenterology"},{"key":"92282_CR13","doi-asserted-by":"publisher","first-page":"169642","DOI":"10.1016\/j.scitotenv.2023.169642","volume":"913","author":"Q Li","year":"2023","unstructured":"Li, Q. et al. Gut microbiota disorders aggravate terbuthylazine-induced mitochondrial quality control disturbance and PANoptosis in chicken hepatocyte through gut-liver axis. Sci. Total Environ. 913, 169642. https:\/\/doi.org\/10.1016\/j.scitotenv.2023.169642 (2023).","journal-title":"Sci. Total Environ."},{"key":"92282_CR14","doi-asserted-by":"publisher","unstructured":"Gao, B., Jeong, W. I. & Tian, Z. Liver: an organ with predominant innate immunity. Hepatology 47(2), 729\u2013736. https:\/\/doi.org\/10.1002\/hep.22034 (2008).","DOI":"10.1002\/hep.22034"},{"issue":"6","key":"92282_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster, S. et al. Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 15(6), 349\u2013364. https:\/\/doi.org\/10.1038\/s41575-018-0009-6 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"92282_CR16","doi-asserted-by":"publisher","unstructured":"Novo, E. et al. The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells. J. Pathol. 226(4), 588\u2013597. https:\/\/doi.org\/10.1002\/path.3005 (2012).","DOI":"10.1002\/path.3005"},{"key":"92282_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/b978-0-12-405211-6.00006-1","volume":"59","author":"J Petrasek","year":"2013","unstructured":"Petrasek, J., Csak, T. & Szabo, G. Toll-like receptors in liver disease. Adv. Clin. Chem. 59, 155\u2013201. https:\/\/doi.org\/10.1016\/b978-0-12-405211-6.00006-1 (2013).","journal-title":"Adv. Clin. Chem."},{"issue":"5","key":"92282_CR18","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1053\/j.gastro.2005.09.004","volume":"129","author":"A Dela Pe\u00f1a","year":"2005","unstructured":"Dela Pe\u00f1a, A. et al. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 129(5), 1663\u20131674. https:\/\/doi.org\/10.1053\/j.gastro.2005.09.004 (2005).","journal-title":"Gastroenterology"},{"issue":"42","key":"92282_CR19","doi-asserted-by":"publisher","first-page":"22011","DOI":"10.1074\/jbc.M116.715953","volume":"291","author":"MC Luo","year":"2016","unstructured":"Luo, M. C. et al. Runt-related transcription factor 1 (RUNX1) binds to p50 in macrophages and enhances TLR4-triggered inflammation and septic shock. J. Biol. Chem. 291(42), 22011\u201322020. https:\/\/doi.org\/10.1074\/jbc.M116.715953 (2016).","journal-title":"J. Biol. Chem."},{"issue":"47","key":"92282_CR20","doi-asserted-by":"publisher","first-page":"8355","DOI":"10.3748\/wjg.v23.i47.8355","volume":"23","author":"K Kaji","year":"2017","unstructured":"Kaji, K. et al. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut Microbiome diversity. World J. Gastroenterol. 23(47), 8355\u20138366. https:\/\/doi.org\/10.3748\/wjg.v23.i47.8355 (2017).","journal-title":"World J. Gastroenterol."},{"issue":"7","key":"92282_CR21","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/meg.0000000000000348","volume":"27","author":"V Gangarapu","year":"2015","unstructured":"Gangarapu, V. et al. Efficacy of rifaximin on Circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 27(7), 840\u2013845. https:\/\/doi.org\/10.1097\/meg.0000000000000348 (2015).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"92282_CR22","doi-asserted-by":"publisher","unstructured":"Fujinaga, Y. et al. Effective combination therapy of Angiotensin-II receptor blocker and rifaximin for hepatic fibrosis in rat model of nonalcoholic steatohepatitis. Int. J. Mol. Sci. 21(15). https:\/\/doi.org\/10.3390\/ijms21155589 (2020).","DOI":"10.3390\/ijms21155589"},{"issue":"10","key":"92282_CR23","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.dld.2022.04.012","volume":"54","author":"M Enomoto","year":"2022","unstructured":"Enomoto, M. et al. Rifaximin and Lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis. Dig. Liver Dis. 54(10), 1392\u20131402. https:\/\/doi.org\/10.1016\/j.dld.2022.04.012 (2022).","journal-title":"Dig. Liver Dis."},{"issue":"1","key":"92282_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/hepr.12904","volume":"48","author":"JFL Cobbold","year":"2018","unstructured":"Cobbold, J. F. L. et al. Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study. Hepatol. Res. 48(1), 69\u201377. https:\/\/doi.org\/10.1111\/hepr.12904 (2018).","journal-title":"Hepatol. Res."},{"issue":"13","key":"92282_CR25","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1111\/bph.12955","volume":"172","author":"JC McGrath","year":"2015","unstructured":"McGrath, J. C. & Lilley, E. Implementing guidelines on reporting research using animals (ARRIVE etc.): New requirements for publication in BJP. Br. J. Pharmacol. 172(13), 3189\u20133193. https:\/\/doi.org\/10.1111\/bph.12955 (2015).","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"92282_CR26","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","volume":"59","author":"EASL-EASD-EASO","year":"2016","unstructured":"EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59(6), 1121\u20131140. https:\/\/doi.org\/10.1007\/s00125-016-3902-y (2016).","journal-title":"Diabetologia"},{"key":"92282_CR27","doi-asserted-by":"publisher","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","volume":"1","author":"EM Brunt","year":"2015","unstructured":"Brunt, E. M. et al. Nonalcoholic fatty liver disease. Nat. Rev. Dis. Primers. 1, 15080. https:\/\/doi.org\/10.1038\/nrdp.2015.80 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"92282_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13301","author":"P Bedossa","year":"2017","unstructured":"Bedossa, P. Pathology of non-alcoholic fatty liver disease. Liver Int. 37 Suppl 1, 85\u201389. https:\/\/doi.org\/10.1111\/liv.13301 (2017)."},{"issue":"5","key":"92282_CR29","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61(5), 1547\u20131554. https:\/\/doi.org\/10.1002\/hep.27368 (2015).","journal-title":"Hepatology"},{"key":"92282_CR30","doi-asserted-by":"publisher","unstructured":"Karmen, A., Wroblewski, F. & Ladue, J. S. Transaminase activity in human blood. J. Clin. Invest. 34(1), 126\u2013131. https:\/\/doi.org\/10.1172\/jci103055 (1955).","DOI":"10.1172\/jci103055"},{"issue":"4","key":"92282_CR31","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/hep.22109","volume":"47","author":"WR Kim","year":"2008","unstructured":"Kim, W. R. et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47(4), 1363\u20131370. https:\/\/doi.org\/10.1002\/hep.22109 (2008).","journal-title":"Hepatology"},{"key":"92282_CR32","doi-asserted-by":"publisher","first-page":"817","DOI":"10.17179\/excli2016-800","volume":"15","author":"MR McGill","year":"2016","unstructured":"McGill, M. R. The past and present of serum aminotransferases and the future of liver injury biomarkers. Excli J. 15, 817\u2013828. https:\/\/doi.org\/10.17179\/excli2016-800 (2016).","journal-title":"Excli J."},{"issue":"10","key":"92282_CR33","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/meg.0000000000001232","volume":"30","author":"A Abdel-Razik","year":"2018","unstructured":"Abdel-Razik, A. et al. Rifaximin in nonalcoholic fatty liver disease: Hit multiple targets with a single shot. Eur. J. Gastroenterol. Hepatol. 30(10), 1237\u20131246. https:\/\/doi.org\/10.1097\/meg.0000000000001232 (2018).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"4","key":"92282_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.5009\/gnl.2012.6.4.505","volume":"6","author":"YY Koh","year":"2012","unstructured":"Koh, Y. Y. et al. The effect of intestinal permeability and endotoxemia on the prognosis of acute pancreatitis. Gut Liver. 6(4), 505\u2013511. https:\/\/doi.org\/10.5009\/gnl.2012.6.4.505 (2012).","journal-title":"Gut Liver"},{"key":"92282_CR35","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3389\/fncel.2015.00392","volume":"9","author":"JR Kelly","year":"2015","unstructured":"Kelly, J. R. et al. Breaking down the barriers: The gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front. Cell. Neurosci. 9, 392. https:\/\/doi.org\/10.3389\/fncel.2015.00392 (2015).","journal-title":"Front. Cell. Neurosci."},{"key":"92282_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fcimb.2019.00044","volume":"9","author":"L Yang","year":"2019","unstructured":"Yang, L. et al. Rifaximin alters intestinal microbiota and prevents progression of ankylosing spondylitis in mice. Front. Cell. Infect. Microbiol. 9, 44. https:\/\/doi.org\/10.3389\/fcimb.2019.00044 (2019).","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"3","key":"92282_CR37","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1083\/jcb.103.3.755","volume":"103","author":"BR Stevenson","year":"1986","unstructured":"Stevenson, B. R. et al. Identification of ZO-1: A high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J. Cell. Biol. 103(3), 755\u2013766. https:\/\/doi.org\/10.1083\/jcb.103.3.755 (1986).","journal-title":"J. Cell. Biol."},{"issue":"6","key":"92282_CR38","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/13543784.2018.1483333","volume":"27","author":"LR Lopetuso","year":"2018","unstructured":"Lopetuso, L. R. et al. The intriguing role of rifaximin in gut barrier chronic inflammation and in the treatment of Crohn\u2019s disease. Expert Opin. Investig. Drugs. 27(6), 543\u2013551. https:\/\/doi.org\/10.1080\/13543784.2018.1483333 (2018).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"92282_CR39","doi-asserted-by":"publisher","unstructured":"Xu, D. et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 146(2), 484\u2013496. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.026 (2014).","DOI":"10.1053\/j.gastro.2013.10.026"},{"issue":"6","key":"92282_CR40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/MPG.0b013e3181c7bdf1","volume":"50","author":"A Alisi","year":"2010","unstructured":"Alisi, A. et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 50(6), 645\u2013649. https:\/\/doi.org\/10.1097\/MPG.0b013e3181c7bdf1 (2010).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"7","key":"92282_CR41","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/j.1478-3231.2008.01723.x","volume":"28","author":"A Farhadi","year":"2008","unstructured":"Farhadi, A. et al. Susceptibility to gut leakiness: A possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int. 28(7), 1026\u20131033. https:\/\/doi.org\/10.1111\/j.1478-3231.2008.01723.x (2008).","journal-title":"Liver Int."},{"issue":"6","key":"92282_CR42","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.jhep.2013.01.038","volume":"58","author":"J Du Plessis","year":"2013","unstructured":"Du Plessis, J. et al. Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that May disrupt intestinal barrier function. J. Hepatol. 58(6), 1125\u20131132. https:\/\/doi.org\/10.1016\/j.jhep.2013.01.038 (2013).","journal-title":"J. Hepatol."},{"issue":"2","key":"92282_CR43","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2009.03.019","volume":"51","author":"CK Argo","year":"2009","unstructured":"Argo, C. K. et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 51(2), 371\u2013379. https:\/\/doi.org\/10.1016\/j.jhep.2009.03.019 (2009).","journal-title":"J. Hepatol."},{"key":"92282_CR44","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","volume":"11","author":"T Hardy","year":"2016","unstructured":"Hardy, T. et al. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu. Rev. Pathol. 11, 451\u2013496. https:\/\/doi.org\/10.1146\/annurev-pathol-012615-044224 (2016).","journal-title":"Annu. Rev. Pathol."},{"issue":"12","key":"92282_CR45","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1096\/fj.201700394R","volume":"31","author":"B Rius","year":"2017","unstructured":"Rius, B. et al. The specialized proresolving lipid mediator Maresin 1 protects hepatocytes from lipotoxic and hypoxia-induced Endoplasmic reticulum stress. Faseb J. 31(12), 5384\u20135398. https:\/\/doi.org\/10.1096\/fj.201700394R (2017).","journal-title":"Faseb J."},{"key":"92282_CR46","doi-asserted-by":"publisher","first-page":"880298","DOI":"10.3389\/fimmu.2022.880298","volume":"13","author":"Y Duan","year":"2022","unstructured":"Duan, Y. et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease. Front. Immunol. 13, 880298. https:\/\/doi.org\/10.3389\/fimmu.2022.880298 (2022).","journal-title":"Front. Immunol."},{"key":"92282_CR47","doi-asserted-by":"publisher","first-page":"154241","DOI":"10.1016\/j.phymed.2022.154241","volume":"104","author":"YF Deng","year":"2022","unstructured":"Deng, Y. F. et al. Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-\u03baB\/NLRP3 signaling pathway. Phytomedicine 104, 154241. https:\/\/doi.org\/10.1016\/j.phymed.2022.154241 (2022).","journal-title":"Phytomedicine"},{"key":"92282_CR48","doi-asserted-by":"publisher","unstructured":"Miura, K. et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 139(1), 323\u2013347. https:\/\/doi.org\/10.1053\/j.gastro.2010.03.052 (2010).","DOI":"10.1053\/j.gastro.2010.03.052"},{"issue":"5","key":"92282_CR49","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jhep.2011.01.048","volume":"55","author":"Y Kamari","year":"2011","unstructured":"Kamari, Y. et al. Lack of interleukin-1\u03b1 or interleukin-1\u03b2 inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J. Hepatol. 55(5), 1086\u20131094. https:\/\/doi.org\/10.1016\/j.jhep.2011.01.048 (2011).","journal-title":"J. Hepatol."},{"issue":"2","key":"92282_CR50","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/hep.23337","volume":"51","author":"R Stienstra","year":"2010","unstructured":"Stienstra, R. et al. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 51(2), 511\u2013522. https:\/\/doi.org\/10.1002\/hep.23337 (2010).","journal-title":"Hepatology"},{"key":"92282_CR51","doi-asserted-by":"publisher","unstructured":"Aoyama, T., Paik, Y. H. & Seki, E. Toll-like receptor signaling and liver fibrosis. Gastroenterol. Res. Pract.. https:\/\/doi.org\/10.1155\/2010\/192543 (2010).","DOI":"10.1155\/2010\/192543"},{"key":"92282_CR52","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","volume":"6","author":"V Hernandez-Gea","year":"2011","unstructured":"Hernandez-Gea, V. & Friedman, S. L. Pathogenesis of liver fibrosis. Annu. Rev. Pathol. 6, 425\u2013456. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130246 (2011).","journal-title":"Annu. Rev. Pathol."},{"issue":"12","key":"92282_CR53","first-page":"759","volume":"100","author":"A Smith","year":"2019","unstructured":"Smith, A., Baumgartner, K. & Bositis, C. Cirrhosis: Diagnosis and management. Am. Fam Physician. 100(12), 759\u2013770 (2019).","journal-title":"Am. Fam Physician"},{"issue":"2","key":"92282_CR54","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.cmet.2020.10.026","volume":"33","author":"P Trivedi","year":"2021","unstructured":"Trivedi, P., Wang, S. & Friedman, S. L. The power of plasticity-metabolic regulation of hepatic stellate cells. Cell. Metab. 33(2), 242\u2013257. https:\/\/doi.org\/10.1016\/j.cmet.2020.10.026 (2021).","journal-title":"Cell. Metab."},{"issue":"7","key":"92282_CR55","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14(7), 397\u2013411. https:\/\/doi.org\/10.1038\/nrgastro.2017.38 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"92282_CR56","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/hep.32204","volume":"75","author":"AJ Sanyal","year":"2022","unstructured":"Sanyal, A. J. et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology 75(5), 1235\u20131246. https:\/\/doi.org\/10.1002\/hep.32204 (2022).","journal-title":"Hepatology"},{"issue":"3","key":"92282_CR57","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/hep.32569","volume":"77","author":"KE Kim","year":"2023","unstructured":"Kim, K. E. et al. Lipocalin-2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high-fat diet-fed Ob\/Ob mice. Hepatology 77(3), 888\u2013901. https:\/\/doi.org\/10.1002\/hep.32569 (2023).","journal-title":"Hepatology"},{"issue":"19","key":"92282_CR58","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9, J. & Sheppard, D. TGF-\u03b2 signaling in health and disease. Cell 186(19), 4007\u20134037. https:\/\/doi.org\/10.1016\/j.cell.2023.07.036 (2023).","journal-title":"Cell"},{"issue":"4","key":"92282_CR59","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2011.11.013","volume":"56","author":"Q Zhu","year":"2012","unstructured":"Zhu, Q. et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J. Hepatol. 56(4), 893\u2013899. https:\/\/doi.org\/10.1016\/j.jhep.2011.11.013 (2012).","journal-title":"J. Hepatol."},{"issue":"6797","key":"92282_CR60","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/35021228","volume":"406","author":"A Aderem","year":"2000","unstructured":"Aderem, A. & Ulevitch, R. J. Toll-like receptors in the induction of the innate immune response. Nature 406(6797), 782\u2013787. https:\/\/doi.org\/10.1038\/35021228 (2000).","journal-title":"Nature"},{"issue":"0 1","key":"92282_CR61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jgh.12019","volume":"28","author":"YS Roh","year":"2013","unstructured":"Roh, Y. S. & Seki, E. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J. Gastroenterol. Hepatol. 28(01), 38\u201342. https:\/\/doi.org\/10.1111\/jgh.12019 (2013).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"92282_CR62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cyto.2008.01.006","volume":"42","author":"YC Lu","year":"2008","unstructured":"Lu, Y. C., Yeh, W. C. & Ohashi, P. S. LPS\/TLR4 signal transduction pathway. Cytokine 42(2), 145\u2013151. https:\/\/doi.org\/10.1016\/j.cyto.2008.01.006 (2008).","journal-title":"Cytokine"},{"issue":"7","key":"92282_CR63","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.ajpath.2015.03.024","volume":"185","author":"S Das","year":"2015","unstructured":"Das, S. et al. Oxidase-Derived peroxynitrite drives inflammation in mice and human nonalcoholic steatohepatitis via TLR4-Lipid raft recruitment. Am. J. Pathol. 185(7), 1944\u20131957. https:\/\/doi.org\/10.1016\/j.ajpath.2015.03.024 (2015).","journal-title":"Am. J. Pathol."},{"key":"92282_CR64","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.tox.2012.10.025","volume":"303","author":"H Shi","year":"2013","unstructured":"Shi, H. et al. Chlorogenic acid reduces liver inflammation and fibrosis through Inhibition of toll-like receptor 4 signaling pathway. Toxicology 303, 107\u2013114. https:\/\/doi.org\/10.1016\/j.tox.2012.10.025 (2013).","journal-title":"Toxicology"},{"key":"92282_CR65","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.freeradbiomed.2017.01.027","volume":"109","author":"P Wenzel","year":"2017","unstructured":"Wenzel, P. et al. Redox regulation of cardiovascular inflammation - Immunomodulatory function of mitochondrial and Nox-derived reactive oxygen and nitrogen species. Free Radic Biol. Med. 109, 48\u201360. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2017.01.027 (2017).","journal-title":"Free Radic Biol. Med."},{"issue":"3","key":"92282_CR66","doi-asserted-by":"publisher","first-page":"G433","DOI":"10.1152\/ajpgi.00163.2009","volume":"300","author":"T Csak","year":"2011","unstructured":"Csak, T. et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 300(3), G433\u2013G441. https:\/\/doi.org\/10.1152\/ajpgi.00163.2009 (2011).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"92282_CR67","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jcmgh.2016.12.004","volume":"3","author":"L Yang","year":"2017","unstructured":"Yang, L. et al. Differentially regulates hepatic steatosis and inflammation\/fibrosis in mice. Cell. Mol. Gastroenterol. Hepatol. 3(3), 469\u2013483. https:\/\/doi.org\/10.1016\/j.jcmgh.2016.12.004 (2017).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"4","key":"92282_CR68","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/hep.23122","volume":"50","author":"A Spruss","year":"2009","unstructured":"Spruss, A. et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 50(4), 1094\u20131104. https:\/\/doi.org\/10.1002\/hep.23122 (2009).","journal-title":"Hepatology"},{"issue":"32","key":"92282_CR69","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.4254\/wjh.v8.i32.1354","volume":"8","author":"S Kiziltas","year":"2016","unstructured":"Kiziltas, S. Toll-like receptors in pathophysiology of liver diseases. World J. Hepatol. 8(32), 1354\u20131369. https:\/\/doi.org\/10.4254\/wjh.v8.i32.1354 (2016).","journal-title":"World J. Hepatol."},{"issue":"1","key":"92282_CR70","doi-asserted-by":"publisher","first-page":"17815","DOI":"10.1038\/s41598-021-97346-9","volume":"11","author":"A Baumann","year":"2021","unstructured":"Baumann, A. et al. Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease. Sci. Rep. 11(1), 17815. https:\/\/doi.org\/10.1038\/s41598-021-97346-9 (2021).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92282-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92282-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92282-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T18:35:52Z","timestamp":1742582152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92282-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92282"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92282-4","relation":{"references":[{"id-type":"doi","id":"10.1111\/liv.13301","asserted-by":"subject"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"29 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was reviewed and approved by [the Medical Ethics Committee of the Second Affiliated Hospital of Fujian Medical University] with the approval number: [251], dated [May 27, 2022].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}}],"article-number":"9815"}}